Scarica l'app Stockscreener
11.84
1.66%
-0.20
Dopo l'orario di chiusura:
11.84
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$12.04
Aprire:
$12.02
Volume 24 ore:
494.83K
Relative Volume:
0.64
Capitalizzazione di mercato:
$816.10M
Reddito:
$46.02M
Utile/perdita netta:
$-70.80M
Rapporto P/E:
-6.5055
EPS:
-1.82
Flusso di cassa netto:
$-1.61M
1 W Prestazione:
+2.87%
1M Prestazione:
+12.98%
6M Prestazione:
+90.05%
1 anno Prestazione:
+30.25%
Intervallo 1D:
$11.72
$12.24
Intervallo di 1 settimana:
$11.05
$12.24
Portata 52W:
$3.91
$13.98
Eyepoint Pharmaceuticals Inc Stock (EYPT) Company Profile
Nome
Eyepoint Pharmaceuticals Inc
Settore
Industria
Telefono
617-926-5000
Indirizzo
480 PLEASANT STREET, WATERTOWN, MA
Confronta EYPT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EYPT
Eyepoint Pharmaceuticals Inc
|
11.84 | 829.89M | 46.02M | -70.80M | -1.61M | -1.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
389.08 | 99.27B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
586.96 | 62.28B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.18 | 59.14B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
707.96 | 43.34B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
300.14 | 36.72B | 3.81B | -644.79M | -669.77M | -6.24 |
Eyepoint Pharmaceuticals Inc Stock (EYPT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-17 | Iniziato | RBC Capital Mkts | Outperform |
| 2025-01-07 | Iniziato | Citigroup | Buy |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-08-28 | Iniziato | Jefferies | Buy |
| 2024-01-22 | Iniziato | JP Morgan | Overweight |
| 2023-11-02 | Iniziato | Mizuho | Buy |
| 2023-04-21 | Iniziato | Robert W. Baird | Outperform |
| 2022-07-07 | Iniziato | Chardan Capital Markets | Buy |
| 2021-03-01 | Iniziato | Cowen | Outperform |
| 2021-01-28 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-04-06 | Downgrade | B. Riley FBR | Buy → Neutral |
| 2019-11-04 | Ripresa | Laidlaw | Buy |
| 2019-09-12 | Iniziato | Guggenheim | Buy |
Mostra tutto
Eyepoint Pharmaceuticals Inc Borsa (EYPT) Ultime notizie
How to recover losses in EyePoint Pharmaceuticals Inc. stock2025 Big Picture & Scalable Portfolio Growth Ideas - Newser
News impact scoring models applied to EyePoint Pharmaceuticals Inc.Trade Exit Report & Consistent Profit Trading Strategies - Newser
EyePoint Pharmaceuticals Inc. stock daily chart insights2025 Trade Ideas & Weekly Watchlist for Hot Stocks - Newser
Using economic indicators to assess EyePoint Pharmaceuticals Inc. potential2025 Institutional Moves & Weekly Watchlist for Hot Stocks - Newser
Quantitative breakdown of EyePoint Pharmaceuticals Inc. recent move2025 Price Targets & Weekly Stock Breakout Alerts - Newser
Evaluating EyePoint Pharmaceuticals Inc. with trendline analysisEarnings Risk Summary & Advanced Technical Analysis Signals - Newser
Key metrics from EyePoint Pharmaceuticals Inc.’s quarterly data2025 Stock Rankings & Safe Entry Trade Reports - Newser
Sector ETF performance correlation with EyePoint Pharmaceuticals Inc.Dollar Strength & AI Optimized Trade Strategies - Newser
Signal strength of EyePoint Pharmaceuticals Inc. stock in tech scannersBear Alert & AI Powered Buy and Sell Recommendations - Newser
EyePoint Announces Participation at Upcoming Investor Conferences | EYPT Stock News - GuruFocus
EyePoint Pharmaceuticals to participate in upcoming conferences. - AInvest
EyePoint Announces Participation at Upcoming Investor Conferences - EyePoint Pharmaceuticals
Leading Retinal Disease Biotech EyePoint Pharmaceuticals Featured at Major September Healthcare Forums - Stock Titan
What to do if you’re stuck in EyePoint Pharmaceuticals Inc.Portfolio Return Report & Low Drawdown Trading Strategies - Newser
Can a trend reversal in EyePoint Pharmaceuticals Inc. lead to recoveryJuly 2025 Institutional & Safe Investment Capital Preservation Plans - Newser
Multi factor analysis applied to EyePoint Pharmaceuticals Inc.Market Sentiment Summary & Risk Adjusted Buy/Sell Alerts - Newser
Is EyePoint Pharmaceuticals Inc. Stock Overbought or Oversold RSI Indicator AnalysisVolume Spike & Fast Exit Strategy with Risk Control - Newser
Advanced analytics toolkit walkthrough for EyePoint Pharmaceuticals Inc.Jobs Report & Verified Swing Trading Watchlist - Newser
What’s the analyst consensus on EyePoint Pharmaceuticals Inc.July 2025 Outlook & Safe Entry Point Identification - theviewers.co.kr
What’s EyePoint Pharmaceuticals Inc.’s historical return2025 Stock Rankings & Momentum Based Trading Signals - theviewers.co.kr
Published on: 2025-08-23 01:34:37 - beatles.ru
Published on: 2025-08-22 23:34:22 - beatles.ru
Should I invest in EyePoint Pharmaceuticals Inc. before earningsJuly 2025 Opening Moves & Community Verified Trade Alerts - theviewers.co.kr
EyePoint Pharmaceuticals Inc. Bounces Off Moving Average SupportJuly 2025 Retail & Growth Focused Entry Point Reports - beatles.ru
Custom watchlist performance reports with EyePoint Pharmaceuticals Inc.July 2025 Drop Watch & Smart Allocation Stock Reports - Newser
Why EyePoint Pharmaceuticals Inc. stock attracts strong analyst attentionJuly 2025 Weekly Recap & Real-Time Chart Pattern Alerts - Newser
Real time alert setup for EyePoint Pharmaceuticals Inc. performanceQuarterly Earnings Report & Risk Controlled Daily Plans - Newser
Will a bounce in EyePoint Pharmaceuticals Inc. offer an exitWeekly Risk Summary & Precise Swing Trade Alerts - Newser
Is EyePoint Pharmaceuticals Inc. still worth holding after the dip2025 Dividend Review & Verified Entry Point Detection - Newser
Using fundamentals and technicals on EyePoint Pharmaceuticals Inc.Gap Down & Comprehensive Market Scan Reports - Newser
EyePoint Pharmaceuticals Inc. Stock Chart Analysis: Bullish or Bearish Pattern FormingDollar Strength & Real-Time Market Trend Scan - Newser
Short interest data insights for EyePoint Pharmaceuticals Inc.Trade Exit Summary & Low Risk High Win Rate Picks - Newser
Strategies to average down on EyePoint Pharmaceuticals Inc.2025 Trading Recap & Low Risk High Reward Ideas - Newser
Published on: 2025-08-19 03:16:46 - Newser
EyePoint Reports Inducement Grants Under NASDAQ Listing - MSN
EyePoint Pharmaceuticals Grants Stock Options to New Employees Under NASDAQ Listing Rule 5635(c)(4) - AInvest
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
EyePoint reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
18,000 Stock Options at $11.09: EyePoint Pharmaceuticals Awards Inducement Grants to Key New Hires - Stock Titan
Live market analysis of EyePoint Pharmaceuticals Inc.Risk Management & Weekly Setup with High ROI Potential - Newser
Can momentum traders help lift EyePoint Pharmaceuticals Inc.Wall Street Watch & Risk Adjusted Buy/Sell Alerts - Newser
Will EyePoint Pharmaceuticals Inc. Reverse From Oversold ConditionsQuarterly Profit Summary & Low Risk Investment Opportunities - sundaytimes.kr
How EyePoint Pharmaceuticals Inc. stock reacts to Fed policy changesQuarterly Portfolio Review & Consistent Growth Equity Picks - Newser
What is the next catalyst for EyePoint Pharmaceuticals Inc.Rate Hike & Technical Pattern Recognition Alerts - 더경남뉴스
Eyepoint Pharmaceuticals Inc Azioni (EYPT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.98%
8.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):